GSK to open vaccine-research facility in Maryland
The U.K.-based company said the facility will allow it to boost its U.S. presence and will join others based in Rixensart, Belgium, and Siena, Italy. The Rockville site was previously occupied by Novartis.
“As the global vaccines leader, GSK is on the cutting edge of vaccine development," GSK Vaccines President Luc Debruyne said. "Following the acquisition of Novartis’ global vaccines business and in recognition of the vaccines knowledge and expertise in the United States, we are pleased to expand our U.S. presence with the creation of a world-class vaccines R&D center. This will drive innovation and enhance our capabilities for new vaccine discoveries that protect the U.S. and public health around the world.”
The new facility's focus largely will be on threats and potential threats to public health, especially those deemed priorities by the U.S. government and its defense and health departments. The Maryland facility also will work with GSK development facilities located in Philadelphia and Cambridge, Massachusetts.
“I am proud that a world-class pharmaceutical company like GSK has chosen to grow its U.S. operations in Maryland," Maryland Gov. Larry Hogan said. "With key federal labs like the Food and Drug Administration and the National Institutes of Health in our backyard, a highly educated work force and a critical mass of life sciences companies, Maryland offers GSK an excellent environment in which to grow and thrive.”